Evidence map›Paper›PMID 42034070›Full record

ReviewEarly human development2026

Retinopathy of prematurity: Moving beyond oxygen.

Steven E Brooks, Christiane E L Dammann, Olaf Dammann

Abstract readReview
In one paragraph

Review in Early human development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Steven E BrooksDept. of Ophthalmology, Medical College of Georgia, Augusta, GA, United States of America.
Christiane E L DammannTufts Medicine Pediatrics/Boston Children's Hospital, Boston, MA, United States of America.
Olaf DammannDept. of Public Health & Community Medicine, Tufts University School of Medicine, Boston, MA, United States of America; Dept. of Neuromedicine & Movement Science, Norwegian University of Science and Technology, Trondheim, Norway; Dept. of Pediatrics, Tufts University School of Medicine, Boston, MA, United States of America; Dept. of Ophthalmology, Tufts University School of Medicine, Boston, MA, United States of America. Electronic address: olaf.dammann@tufts.edu.

Funding

Planning the VICTORY (VIsual ComplicaTions Of PrematuRitY) StudyR34EY034969 · NEI · TUFTS UNIVERSITY BOSTON · PI DAMMANN, OLAF · 2023 to 2024
$545k
NEI NIH HHS R34 EY034969
6 · The paper itself

Abstract

Retinopathy of prematurity (ROP) is a vision-threatening disease among very preterm newborns in high-income countries and also in gestationally older newborns in low resource settings. The main classic risk factor and purported causal culprit is exogenous oxygen, which regulates angiogenic growth factors in the two phases of the disease. Along these lines, the vast majority of animal studies use oxygen-induced retinopathy models, with very limited data coming from non-oxygen models. We make the case in favor of alternative etiological paradigms and call for more models that employ infection and inflammation-associated exposures. We support our argument by reference to recent experimental and clinical data.

Indexed as

OxygenRetinopathy of PrematurityAnimalsHumansInfant, NewbornOxygenInfectionInflammationNewbornOxygenPretermRetinopathy of prematurity

Identifiers

PMID42034070
PMCPMC13487492

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.